You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Type 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients

    SBC: Mercury Biomed LLC            Topic: 300

    Project SummaryAbstractThis proposal presents Phase II of Mercury Biomedandapos s plan for commercializing the new and innovative WarmSmart technology to more effectively keep surgical patients normothermicWarmSmart embodies several breakthrough concepts in bioheat transfer to manage core temperatureWe are building a costcompetitive patient warming technology that will be superior to existing tech ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: Bertec Corporation            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging population, yet the neurological,sensory, and motor changes that lead to increased fall risk often escape early identification and intervention. Vital signs are commonly used in clinical settings to assess the cardiovascular system (blood pressure, heart rate), immune system (body temperature), and the respiratory system ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Create Ultralong DNA Constructs in One Assembly Step

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 400

    Create Ultralong DNA Constructs in One Assembly Step Firebird Biomolecular Sciences LLCSteven ABenner Foundation for Applied Molecular EvolutionShuichi Hoshika AbstractFrost andampSullivan found aglobal market for DNA oligos at $million$million for genesPrivate investment in DNA synthesis companies like TwistGinkgoand DNA Script give collective valuations of several billion dollarsFederal public i ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Compatibility between Brain-Computer Interface and High-Efficiency Augmentative and Alternative Communication Systems

    SBC: Prentke Romich Company            Topic: NIDCD

    Compatibility Between Brain-Computer Interface and High Efficiency Augmentative and Alternative Communication Systems: Phase II ABSTRACTBrain-computer interfaces (BCI) enable text production for people who cannot move, but have only simple communication interfaces and are not widely used. Augmentative and alternative communication (AAC) systems are widely used and give efficient and precise commun ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Oxygen Production and Delivery on Demand

    SBC: Global Research and Development Inc.            Topic: DHP17B005

    This Phase II proposal is in response to the Defense Health Agency 2017 SBIR topic 17B-005. The approach is an electrochemical membrane oxygen pump using newly developed nano-thickness membrane technology. The total membrane with all the layers is less

    STTR Phase II 2019 Department of DefenseDefense Health Program
US Flag An Official Website of the United States Government